US Pharma MarketingInfex Therapeutics is pushing ahead with development of a non-cystic fibrosis bronchiectasis drug candidate after posting phase 2a data, advancing efforts to add to the options for treating patients who recently gained access to Insmed’s Brinsupri.
Infex, following in Insmed’s footsteps, advances lung disease candidate after clearing phase 2a
Infex, following in Insmed’s footsteps, advances lung disease candidate after clearing phase 2a is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Source: FierceBiotech